Loading...
Loading...
CYAD| Name | Value |
|---|---|
| Revenues | 14.0K |
| Cost of Revenue | 9.0K |
| Gross Profit | 5.0K |
| Operating Expense | 3,088.0K |
| Operating I/L | -3,083.0K |
| Other Income/Expense | 4.0K |
| Interest Income | 0.0K |
| Pretax | -3,079.0K |
| Income Tax Expense | -34.0K |
| Net Income/Loss | -3,044.0K |
Celyad Oncology SA is a clinical-stage biopharmaceutical company specializing in the development of chimeric antigen receptor T (CAR-T) cell therapies for cancer treatment. The company's lead product candidates include allogeneic and autologous CAR-T candidates for the treatment of metastatic colorectal cancer, relapsed/refractory multiple myeloma, acute myeloid leukemia, and myelodysplastic syndromes. Additionally, Celyad Oncology SA has a preclinical candidate for the treatment of solid tumors. The company generates revenue through the development and potential commercialization of its CAR-T therapies, as well as through licensing agreements and research collaborations with other biopharmaceutical companies.
